X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

Yuvraj_pawp by Yuvraj_pawp
16th November 2017
in Europe, News

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.

Dr Ryan Cawood, CEO of Oxford Genetics said, “This license agreement with Twist Bioscience serves as further recognition of our approach to developing the best optimised expression vectors. By utilising our SnapFast™ platform, Twist Bioscience is giving its customers access to the latest vector designs for the most demanding applications and providing them with better value, a streamlined workflow and maximum flexibility in order to utilise their custom DNA constructs to their best effect.”

Oxford Genetics specialises in the design of application specific vectors, which is a culmination of access to cutting edge bioinformatics, generation of extensive biological data, and continual refinement to ensure customer success. The vectors also grant access to the wider SnapFast™ ecosystem which allows Twist Bioscience to switch between all of Oxford Genetics’ vectors, making future changes and additions simple and efficient.

Emily M. Leproust, Ph.D., CEO of Twist Bioscience commented, “By complementing our ability to provide high throughput synthetic genes with a wide range of customized vectors from Oxford Genetics, we accelerate our customer’s workflow, allowing them to solve more complex problems while saving both time and resources. Importantly, it enables us to reach the large group of customers who order smaller quantities of genes in standard vectors. We remain committed to optimizing our product line to enable our customers to succeed more quickly.”

Previous Post

Webflow Mobile App Launch

Next Post

LabCorp Announces New Expanded Use For PD-L1 Test With Bristol-Myers Squibb’s OPDIVO®

Related Posts

DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Europe

Pharma Sector Seeks Seamless EU Medical Device Rules

24th March 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Drug Development

Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

21st March 2025
Clinical Trials

Oracle Wins the Asia Pacific Biopharma Excellence Awards

21st March 2025
Next Post

LabCorp Announces New Expanded Use For PD-L1 Test With Bristol-Myers Squibb’s OPDIVO®

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In